🇺🇸 FDA
Patent

US 7354939

Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto

granted A61PA61P1/04A61P1/16

Quick answer

US patent 7354939 (Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto) held by Vertex Pharmaceuticals Incorporated expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Apr 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P1/04, A61P1/16, A61P1/18, A61P15/00